Rhumbline Advisers Ocular Therapeutix, Inc Transaction History

Rhumbline Advisers

  • $121 Billion
  • Q3 2025

A detailed history of Rhumbline Advisers transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Rhumbline Advisers holds 220,008 shares of OCUL stock, worth $2.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
220,008
Previous 225,548 2.46%
Holding current value
$2.5 Million
Previous $2.09 Million 22.84%
% of portfolio
0.0%
Previous 0.0%

Shares

34 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 06, 2025
SELL
$9.09 - $13.6 $50,358 - $75,344
-5,540 Reduced 2.46%
220,008 $2.57 Million
Q2 2025

Aug 12, 2025
BUY
$6.02 - $9.46 $14,646 - $23,016
2,433 Added 1.09%
225,548 $2.09 Million
Q1 2025

Apr 08, 2025
BUY
$5.93 - $9.08 $56,418 - $86,387
9,514 Added 4.45%
223,115 $1.69 Million
Q4 2024

May 29, 2025
SELL
$8.33 - $11.47 $79,251 - $109,125
-9,514 Reduced 4.26%
213,601 $1.82 Million
Q4 2024

Jan 30, 2025
BUY
$8.33 - $11.47 $47,331 - $65,172
5,682 Added 2.73%
213,601 $1.82 Million
Q3 2024

Nov 12, 2024
SELL
$6.45 - $9.23 $21,813 - $31,215
-3,382 Reduced 1.6%
207,919 $1.81 Million
Q2 2024

Aug 01, 2024
BUY
$4.2 - $8.69 $249,249 - $515,708
59,345 Added 39.05%
211,301 $1.45 Million
Q1 2024

May 09, 2024
BUY
$3.85 - $10.93 $146,265 - $415,241
37,991 Added 33.34%
151,956 $1.38 Million
Q4 2023

Feb 08, 2024
SELL
$2.08 - $4.52 $33,386 - $72,550
-16,051 Reduced 12.35%
113,965 $508,000
Q3 2023

Nov 09, 2023
BUY
$3.14 - $5.04 $24,470 - $39,276
7,793 Added 6.38%
130,016 $408,000
Q2 2023

Aug 08, 2023
BUY
$4.6 - $7.64 $66,184 - $109,924
14,388 Added 13.34%
122,223 $630,000
Q1 2023

May 11, 2023
BUY
$2.79 - $6.27 $18,112 - $40,704
6,492 Added 6.41%
107,835 $568,000
Q4 2022

Feb 14, 2023
BUY
$2.61 - $4.41 $5,248 - $8,868
2,011 Added 2.02%
101,343 $285,000
Q3 2022

Nov 10, 2022
BUY
$4.09 - $6.5 $36,143 - $57,440
8,837 Added 9.77%
99,332 $412,000
Q2 2022

Aug 11, 2022
BUY
$3.01 - $5.22 $5,502 - $9,542
1,828 Added 2.06%
90,495 $364,000
Q1 2022

May 12, 2022
BUY
$4.83 - $7.35 $7,481 - $11,385
1,549 Added 1.78%
88,667 $439,000
Q4 2021

Feb 10, 2022
SELL
$6.16 - $12.07 $11,359 - $22,257
-1,844 Reduced 2.07%
87,118 $607,000
Q3 2021

Nov 12, 2021
BUY
$9.7 - $14.34 $37,296 - $55,137
3,845 Added 4.52%
88,962 $890,000
Q2 2021

Aug 05, 2021
BUY
$13.43 - $19.16 $21,367 - $30,483
1,591 Added 1.9%
85,117 $1.21 Million
Q1 2021

May 06, 2021
SELL
$15.82 - $22.11 $34,629 - $48,398
-2,189 Reduced 2.55%
83,526 $1.37 Million
Q4 2020

Feb 10, 2021
BUY
$7.91 - $22.95 $118,452 - $343,676
14,975 Added 21.17%
85,715 $1.77 Million
Q3 2020

Nov 12, 2020
SELL
$7.36 - $9.87 $41,620 - $55,814
-5,655 Reduced 7.4%
70,740 $538,000
Q2 2020

Aug 13, 2020
BUY
$4.67 - $8.95 $89,388 - $171,311
19,141 Added 33.43%
76,395 $636,000
Q1 2020

May 06, 2020
BUY
$3.95 - $7.4 $6,098 - $11,425
1,544 Added 2.77%
57,254 $283,000
Q4 2019

Feb 05, 2020
BUY
$2.57 - $4.73 $12,500 - $23,006
4,864 Added 9.57%
55,710 $220,000
Q3 2019

Oct 23, 2019
BUY
$3.04 - $5.32 $1,839 - $3,218
605 Added 1.2%
50,846 $155,000
Q2 2019

Aug 14, 2019
BUY
$2.46 - $4.52 $19,721 - $36,236
8,017 Added 18.99%
50,241 $221,000
Q1 2019

May 01, 2019
SELL
$3.51 - $4.77 $4,355 - $5,919
-1,241 Reduced 2.86%
42,224 $168,000
Q4 2018

Jan 31, 2019
BUY
$3.87 - $7.11 $56,312 - $103,457
14,551 Added 50.33%
43,465 $173,000
Q3 2018

Nov 07, 2018
SELL
$5.42 - $6.99 $6,980 - $9,003
-1,288 Reduced 4.26%
28,914 $199,000
Q2 2018

Aug 06, 2018
BUY
$5.99 - $8.17 $43,457 - $59,273
7,255 Added 31.62%
30,202 $204,000
Q1 2018

May 02, 2018
BUY
$4.66 - $7.08 $7,572 - $11,505
1,625 Added 7.62%
22,947 $149,000
Q4 2017

Feb 09, 2018
SELL
$3.73 - $6.37 $31,753 - $54,227
-8,513 Reduced 28.53%
21,322 $95,000
Q3 2017

Nov 06, 2017
BUY
$5.28 - $6.88 $157,528 - $205,264
29,835
29,835 $184,000

About OCULAR THERAPEUTIX, INC

OCUL Quotes by TradingView
  • Ticker OCUL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,966,896
  • Market Cap $875M
  • Description
  • Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...
More about OCUL
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email